Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials

Bernard Combe, Frank Behrens, Neil McHugh, Fiona Brock, Urs Kerkmann, Blerina Kola, Gaia Gallo

Research output: Contribution to journalArticle

16 Citations (Scopus)
176 Downloads (Pure)

Abstract

OBJECTIVE: To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA).

METHODS: Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies.

RESULTS: Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire-Disability Index improvement.

CONCLUSION: ETN with and without MTX provided similar benefits in active PsA.

Original languageEnglish
Pages (from-to)1063-1067
JournalThe Journal of Rheumatology
Volume43
Issue number6
Early online date1 May 2016
DOIs
Publication statusPublished - Jun 2016

Fingerprint Dive into the research topics of 'Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials'. Together they form a unique fingerprint.

  • Cite this